Robert Discordia, PhD
Co-Founder, President & Chief Executive Officer Equulus Thrapeutics
Dr. Robert Discordia is Co-Founder, President & CEO of EQUULUS Therapeutics, a biotechnology company focused on developing next-generation therapies for central nervous system disorders, including addiction depression and PTSD. He has over three decades of experience in the pharmaceutical and biotechnology industry.
Seminars
3rd Presentation Session
Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience.
What is this session?
Following the same structure as the two presentation sessions on conference day one, these are further presentation slots, so pharma and investors have more opportunities to listen to pitches from leading biotech across Neuroscience. Whether you are driving a truly transformative therapeutic benefit in rare diseases, addressing residual unmet need in neuroinflammation, or validating new targets in neurodegeneration, this is a more targeted opportunity to share your company profile and differentiation in front of active and interested search and evaluation teams.
10.00 – EQL-988: Expanding Rapid Treatment for Suicidality Beyond Ketamine by EQUULUS Therapeutics
10.15 – Presentation by Treefrog Therapeutics
10.30 – Presentation by Kinoxis Therapeutics
10.45 – Presentation by Beacon Neuroscience
11.00 – Presentation by Crownlands
11.15-12:00 Presentations Available
